Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo. Try Elite Free for 7 Days
Login Sign up free
Home Screener Maps Charts News Groups Insider Futures Forex Crypto Portfolio Calendar
Pricing

New upgrade:   Journal your trades with more detail

Read How
Market News Market Pulse Stocks News ETF News Crypto News

Avalo Therapeutics

Contributing Author

Recent Articles by Avalo Therapeutics

Aug-06
Avalo Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Updates AVTX GlobeNewswire
Jul-22
Avalo Therapeutics to Participate in the BTIG Biotechnology Conference AVTX GlobeNewswire
Jul-07
Avalo Therapeutics to Participate in the Leerink Partners Therapeutics Forum AVTX GlobeNewswire
Jun-26
Avalo Therapeutics to Join the Russell 2000 and Russell 3000 Indexes AVTX GlobeNewswire
Jun-23
Avalo Therapeutics Appoints Ron Philip to Board of Directors AVTX GlobeNewswire
Jun-16
Avalo Therapeutics Expands Pipeline with AVTX-010, a Long-Acting Next-Generation Anti-IL-1β Antibody AVTX GlobeNewswire
May-22
Avalo Therapeutics Announces Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) AVTX GlobeNewswire
May-13
Avalo Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates AVTX GlobeNewswire
May-05
Avalo Therapeutics Announces Pricing of $375 Million Public Offering AVTX +34.13% GlobeNewswire
May-05
Avalo Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants AVTX +18.00% AVTX +34.13% GlobeNewswire
May-05
Avalo Therapeutics Achieves Positive Topline Results in Phase 2 LOTUS Trial of Abdakibart (AVTX-009) in Moderate to Severe Hidradenitis Suppurativa AVTX +18.00% AVTX +34.13% GlobeNewswire
Apr-28
Avalo Therapeutics Purchases Optional Milestone Buyout AVTX -10.82% GlobeNewswire
Mar-23
Avalo Therapeutics Reports 2025 Financial Results and Recent Business Updates AVTX GlobeNewswire
Feb-24
Avalo Therapeutics to Participate in Upcoming Investor Conferences AVTX +9.46% GlobeNewswire
Feb-18
Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) AVTX AVTX +6.47% GlobeNewswire
Feb-04
Avalo Therapeutics to Participate in Upcoming Investor Conferences AVTX -9.96% GlobeNewswire
Nov-17
Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) AVTX +11.68% AVTX +6.67% GlobeNewswire
Nov-06
Avalo Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates AVTX -6.26% GlobeNewswire
Nov-03
Avalo Therapeutics to Participate in Upcoming Investor Conferences AVTX -7.54% GlobeNewswire
Oct-29
Avalo Therapeutics Announces Completion of Enrollment in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa AVTX GlobeNewswire
Oct-01
Avalo Therapeutics Expands Leadership Team with Key Appointments in Business Development and Human Resources AVTX GlobeNewswire
Sep-22
Avalo Therapeutics Appoints Kevin R. Lind to Board of Directors AVTX GlobeNewswire
Aug-27
Avalo Therapeutics to Participate in Upcoming Investor Conferences AVTX GlobeNewswire
Aug-07
Avalo Reports Second Quarter 2025 Financial Results and Recent Business Updates AVTX GlobeNewswire
Jun-23
Avalo Therapeutics to Participate in Upcoming Investor Conferences AVTX GlobeNewswire
Jun-18
Avalo Therapeutics Announces Appointment of Rita Jain, M.D. to Board of Directors AVTX +6.49% GlobeNewswire
May-27
Avalo Therapeutics to Participate in Upcoming Investor Conferences AVTX GlobeNewswire
May-12
Avalo Reports First Quarter 2025 Financial Results and Recent Business Updates AVTX GlobeNewswire
Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Quotes delayed 1 minute for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)